Global health: Neglected diseases and access to medicines

Infectious Disease Clinics of North America

Volumn 25, Issue 3, 2011, Pages 639-651

  Garg, Nisha Jain ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Neglected diseases; Public health; Therapeutics; Vaccines

Indexed keywords

ALBENDAZOLE; AMIKACIN; ANTHELMINTIC AGENT; AZITHROMYCIN; BENZNIDAZOLE; CLOFAZIMINE; DAPSONE; DIETHYLCARBAMAZINE; DOXYCYCLINE; IVERMECTIN; MEBENDAZOLE; NIFURTIMOX; PRAZIQUANTEL; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE;

AFRICAN TRYPANOSOMIASIS; BURULI ULCER; CHAGAS DISEASE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRACUNCULIASIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL SANITATION; EYE SURGERY; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH EDUCATION; HELMINTHIASIS; HOOKWORM INFECTION; HOST PATHOGEN INTERACTION; HUMAN; INFECTION CONTROL; LEISHMANIASIS; LEPROSY; LIFESTYLE MODIFICATION; LYMPHATIC FILARIASIS; NEGLECTED DISEASE; NEMATODIASIS; NONHUMAN; ONCHOCERCIASIS; PEDICULOSIS; PERSONAL HYGIENE; PUBLIC HEALTH; PUBLIC HEALTH PROBLEM; REVIEW; SCABIES; SCHISTOSOMIASIS; SCHISTOSOMIASIS HAEMATOBIA; SCHISTOSOMIASIS JAPONICA; SCHISTOSOMIASIS MANSONI; SINGLE DRUG DOSE; STRONGYLOIDIASIS; TRACHOMA; TRICHURIASIS; UNSPECIFIED SIDE EFFECT; VECTOR CONTROL;

ANIMALS; ANTHELMINTICS; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASE CONTROL; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HELMINTHIASIS; HUMANS; NEGLECTED DISEASES; TROPICAL MEDICINE; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 80052402560     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2011.05.007     Document Type: Review

References (85)

1. Working to overcome the global impact of neglected tropical diseases, in First WHO report on neglected tropical diseases 2010, World Health Organization, World Health Organization, Geneva (Switzerland), p. 1.
2. Hotez P.J., Fenwick A., Savioli L., et al. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 2009, 373:1570.
3. Hotez P.J., Molyneux D.H., Fenwick A., et al. Control of neglected tropical diseases. N Engl J Med 2007, 357:1018.
4. Boutayeb A. Developing countries and neglected diseases: challenges and perspectives. Int J Equity Health 2007, 6:20.
5. Narain J.P., Dash A.P., Parnell B., et al. Elimination of neglected tropical diseases in the South-East Asia Region of the World Health Organization. Bull World Health Organ 2010, 88:206.
6. Moran M., Guzman J., Ropars A.L., et al. Neglected disease research and development: how much are we really spending?. PLoS Med 2009, 6:e30.
7. Bethony J.M., Cole R.N., Guo X., et al. Vaccines to combat the neglected tropical diseases. Immunol Rev 2010, 239:237.
8. Global plan to combat neglected tropical diseases 2007, World Health Organization, World Health Organization, Geneva (Switzerland), p. 1.
9. Utzinger J., Raso G., Brooker S., et al. Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology 2009, 136:1859.
10. Wang L.D., Guo J.G., Wu X.H., et al. China's new strategy to block Schistosoma japonicum transmission: experiences and impact beyond schistosomiasis. Trop Med Int Health 2009, 14:1475.
11. Gustavsen K.M., Bradley M.H., Wright A.L. GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis. Ann Trop Med Parasitol 2009, 103(Suppl 1):S11.
12. Colatrella B. The Mectizan Donation Program: 20 years of successful collaboration - a retrospective. Ann Trop Med Parasitol 2008, 102(Suppl 1):7.
13. Burton M.J., Frick K.D., Bailey R.L., et al. Azithromycin for the treatment and control of trachoma. Expert Opin Pharmacother 2002, 3:113.
14. Sunderkotter C.H., Lan Ma H. Hautarzt 2005, 56:478. [in German].
15. Sebbag R. Bull Acad Natl Med 2007, 191:1601. [in French].
16. Gyapong J.O., Gyapong M., Yellu N., et al. Integration of control of neglected tropical diseases into health-care systems: challenges and opportunities. Lancet 2010, 375:160.
17. Kabatereine N.B., Malecela M., Lado M., et al. How to (or not to) integrate vertical programmes for the control of major neglected tropical diseases in sub-Saharan Africa. PLoS Negl Trop Dis 2010, 4:e755.
18. Keiser J., Utzinger J. The drugs we have and the drugs we need against major helminth infections. Adv Parasitol 2010, 73:197.
19. Olsen A. Efficacy and safety of drug combinations in the treatment of schistosomiasis, soil-transmitted helminthiasis, lymphatic filariasis and onchocerciasis. Trans R Soc Trop Med Hyg 2007, 101:747.
20. Ali B.H. A short review of some pharmacological, therapeutic and toxicological properties of praziquantel in man and animals. Pak J Pharm Sci 2006, 19:170.
21. Brown K.R., Ricci F.M., Ottesen E.A. Ivermectin: effectiveness in lymphatic filariasis. Parasitology 2000, 121(Suppl):S133.
22. Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology 2000, 121(Suppl):S113.
23. Cupp E.W., Sauerbrey M., Richards F. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan (R)) monotherapy. Acta Trop 2010, [Epub ahead of print].
24. Michael E., Malecela-Lazaro M.N., Simonsen P.E., et al. Mathematical modelling and the control of lymphatic filariasis. Lancet Infect Dis 2004, 4:223.
25. Ray K.J., Lietman T.M., Porco T.C., et al. When can antibiotic treatments for trachoma be discontinued? Graduating communities in three African countries. PLoS Negl Trop Dis 2009, 3:e458.
26. Babu B.V., Behera D.K., Kerketta A.S., et al. Use of an inclusive-partnership strategy in urban areas of Orissa, India, to increase compliance in a mass drug administration for the control of lymphatic filariasis. Ann Trop Med Parasitol 2006, 100:621.
27. Smits H.L. Prospects for the control of neglected tropical diseases by mass drug administration. Expert Rev Anti Infect Ther 2009, 7:37.
28. Bethony J., Brooker S., Albonico M., et al. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 2006, 367:1521.
29. Brooker S., Clements A.C., Bundy D.A. Global epidemiology, ecology and control of soil-transmitted helminth infections. Adv Parasitol 2006, 62:221.
30. Brooker S., Hotez P.J., Bundy D.A. The global atlas of helminth infection: mapping the way forward in neglected tropical disease control. PLoS Negl Trop Dis 2010, 4:e779.
31. Keiser J., Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 2008, 299:1937.
32. Haswell-Elkins M.R., Elkins D.B., Manjula K., et al. An investigation of hookworm infection and reinfection following mass anthelmintic treatment in the south Indian fishing community of Vairavankuppam. Parasitology 1988, 96(Pt 3):565.
33. Quinnell R.J., Slater A.F., Tighe P., et al. Reinfection with hookworm after chemotherapy in Papua New Guinea. Parasitology 1993, 106(Pt 4):379.
34. Harfoush M.A., Abd el A.A., El-Seify M.A. Resistance of gastrointestinal nematodes of sheep to some anthelmintics. J Egypt Soc Parasitol 2010, 40:377.
35. Hooper P.J., Bradley M.H., Biswas G., et al. The global programme to eliminate lymphatic filariasis: health impact during its first 8 years (2000-2007). Ann Trop Med Parasitol 2009, 103(Suppl 1):S17.
36. Ottesen E.A. Lymphatic filariasis: treatment, control and elimination. Adv Parasitol 2006, 61:395.
37. de Kraker M.E., Stolk W.A., van Oortmarssen G.J., et al. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti. Trop Med Int Health 2006, 11:718.
38. Ottesen E.A., Hooper P.J., Bradley M., et al. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2008, 2:e317.
39. Addiss D. The 6th Meeting of the Global Alliance to Eliminate Lymphatic Filariasis: a half-time review of lymphatic filariasis elimination and its integration with the control of other neglected tropical diseases. Parasit Vectors 2010, 3:100.
40. Michael E., Gambhir M. Transmission models and management of lymphatic filariasis elimination. Adv Exp Med Biol 2010, 673:157.
41. El-Setouhy M., Abd Elaziz K.M., Helmy H., et al. The effect of compliance on the impact of mass drug administration for elimination of lymphatic filariasis in Egypt. Am J Trop Med Hyg 2007, 77:1069.
42. Sunish I.P., Rajendran R., Mani T.R., et al. Vector control complements mass drug administration against bancroftian filariasis in Tirukoilur, India. Bull World Health Organ 2007, 85:138.
43. Boatin B.A., Richards F.O. Control of onchocerciasis. Adv Parasitol 2006, 61:349.
44. Thylefors B., Alleman M. Towards the elimination of onchocerciasis. Ann Trop Med Parasitol 2006, 100:733.
45. Amazigo U.V., Noma M., Bump J., et al. Onchocerciasis. Disease and mortality in sub-Saharan Africa 2006, World Bank, Washington, DC. D.T. Jamison, R.G. Feachem, M.W. Makgoba (Eds.).
46. Basanez M.G., Pion S.D., Boakes E., et al. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis 2008, 8:310.
47. Seketeli A., Adeoye G., Eyamba A., et al. The achievements and challenges of the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol 2002, 96(Suppl 1):S15.
48. Boatin B. The Onchocerciasis Control Programme in West Africa (OCP). Ann Trop Med Parasitol 2008, 102(Suppl 1):13.
49. Ogoussan K.T., Hopkins A. Mectizan (R) procurement and delivery for onchocerciasis mass drug administration programmes. Acta Trop 2010, [Epub ahead of print].
50. Wkly Epidemiol Rec 2010, 85:321. [in English, French].
51. Osei-Atweneboana M.Y., Eng J.K., Boakye D.A., et al. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 2007, 369:2021.
52. Winnen M., Plaisier A.P., Alley E.S., et al. Can ivermectin mass treatments eliminate onchocerciasis in Africa?. Bull World Health Organ 2002, 80:384.
53. Slatko B.E., Taylor M.J., Foster J.M. The Wolbachia endosymbiont as an anti-filarial nematode target. Symbiosis 2010, 51:55.
54. Zhou X.N., Bergquist R., Leonardo L., et al. Schistosomiasis japonica control and research needs. Adv Parasitol 2010, 72:145.
55. Botros S., El-Lakkany N., Seif El-Din S.H., et al. Comparative efficacy and bioavailability of different praziquantel brands. Exp Parasitol 2011, 127(2):515-521.
56. Gryseels B., Stelma F.F., Talla I., et al. Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal. Trop Geogr Med 1994, 46:209.
57. Ismail M., Botros S., Metwally A., et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 1999, 60:932.
58. Uneke C.J. Soil transmitted helminth infections and schistosomiasis in school age children in sub-Saharan Africa: efficacy of chemotherapeutic intervention since World Health Assembly Resolution 2001. Tanzan J Health Res 2010, 12:86.
59. Hotez P.J., Engels D., Fenwick A., et al. Africa is desperate for praziquantel. Lancet 2010, 376:496.
60. Wright H.R., Turner A., Taylor H.R. Trachoma. Lancet 2008, 371:1945.
61. Burton M.J. Trachoma: an overview. Br Med Bull 2007, 84:99.
62. Yorston D., Mabey D., Hatt S., et al. Interventions for trachoma trichiasis. Cochrane Database Syst Rev 2006, 3. CD004008.
63. Ferriman A. Blinding trachoma almost eliminated from Morocco. BMJ 2001, 323:1387.
64. Thylefors B., Negrel A.D., Pararajasegaram R., et al. Available data on blindness (update 1994). Ophthalmic Epidemiol 1995, 2:5.
65. Melese M., Alemayehu W., Lakew T., et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA 2008, 299:778.
66. Barrett M.P., Gilbert I.H. Perspectives for new drugs against trypanosomiasis and leishmaniasis. Curr Top Med Chem 2002, 2:471.
67. Boscardin S.B., Torrecilhas A.C., Manarin R., et al. Chagas' disease: an update on immune mechanisms and therapeutic strategies. J Cell Mol Med 2010, 14:1373.
68. Paulino M., Iribarne F., Dubin M., et al. The chemotherapy of Chagas' disease: an overview. Mini Rev Med Chem 2005, 5:499.
69. Adams E.R., Hamilton P.B. New molecular tools for the identification of trypanosome species. Future Microbiol 2008, 3:167.
70. Desquesnes M., Davila A.M. Applications of PCR-based tools for detection and identification of animal trypanosomes: a review and perspectives. Vet Parasitol 2002, 109:213.
71. Rodgers J. Human African trypanosomiasis, chemotherapy and CNS disease. J Neuroimmunol 2009, 211:16.
72. Hotez P.J., Pecoul B. " Manifesto" for advancing the control and elimination of neglected tropical diseases. PLoS Negl Trop Dis 2010, 4:e718.
73. Progress toward global eradication of dracunculiasis, January 2009-June 2010. MMWR Morb Mortal Wkly Rep 2010, 59:1239. CDC.
74. Rinaldi A. Free, at last! The progress of new disease eradication campaigns for guinea worm disease and polio, and the prospect of tackling other diseases. EMBO Rep 2009, 10:215.
75. Dracunculiasis eradication - global surveillance summary, 2009. Wkly Epidemiol Rec 2010, 85:166.
76. Hopkins D.R., Ruiz-Tiben E., Downs P., et al. Dracunculiasis eradication: neglected no longer. Am J Trop Med Hyg 2008, 79:474.
77. Cohen J., Dibner M.S., Wilson A. Development of and access to products for neglected diseases. PLoS One 2010, 5:e10610.
78. Trouiller P., Torreele E., Olliaro P., et al. Drugs for neglected diseases: a failure of the market and a public health failure?. Trop Med Int Health 2001, 6:945.
79. Chigusa Y., Ohmae H., Otake H., et al. Effects of repeated praziquantel treatment on schistosomiasis mekongi morbidity as detected by ultrasonography. Parasitol Int 2006, 55:261.
80. Hisakane N., Kirinoki M., Chigusa Y., et al. The evaluation of control measures against Schistosoma mekongi in Cambodia by a mathematical model. Parasitol Int 2008, 57:379.
81. Sinuon M., Tsuyuoka R., Socheat D., et al. Financial costs of deworming children in all primary schools in Cambodia. Trans R Soc Trop Med Hyg 2005, 99:664.
82. Gabrielli A.F., Toure S., Sellin B., et al. A combined school- and community-based campaign targeting all school-age children of Burkina Faso against schistosomiasis and soil-transmitted helminthiasis: performance, financial costs and implications for sustainability. Acta Trop 2006, 99:234.
83. Koukounari A., Gabrielli A.F., Toure S., et al. Schistosoma haematobium infection and morbidity before and after large-scale administration of praziquantel in Burkina Faso. J Infect Dis 2007, 196:659.
84. Toure S., Zhang Y., Bosque-Oliva E., et al. Two-year impact of single praziquantel treatment on infection in the national control programme on schistosomiasis in Burkina Faso. Bull World Health Organ 2008, 86:780.
85. Mrazek M.F., Mossialos E. Stimulating pharmaceutical research and development for neglected diseases. Health Policy 2003, 64:75.